Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

By P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-yehuda, S. Lonial, H. Goldschmidt and 11 more. New England Journal of Medicine, 2005

2,281 citations recorded by the source corpus.

Subfields: Hematology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2f0ca3b1a7ecfca0a8a6fce95c955879f5ec3e35

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. J. Adams

In Oncology

1. S. Rajkumar
2. M. Wicha
3. Suling Liu
4. G. Dontu
5. F. Mantovani
6. A. Letai
7. Licio Collavin
8. G. Del Sal

Citations in the corpus

• A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis (2009, background): “Bortezomib, a dipeptide boronate approved for the treatment of multiple myelom”
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. (2007, background): “myeloma (8) and some forms of non-Hodgkin’s lymphoma (NHL;”
• Improved survival in multiple myeloma and the impact of novel therapies. (2008, background): “The median age at diagnosis was 66 years (21-97), and 1770 (59%) were males.”
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, neutral): “5 mg/L 5 (8) 3 (9) Albumin level, n (%)”
• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. (2012, neutral): “Median creatinine clearance, mL/min (range) 70 (16-203)”